Previously doing business as Microperfusions, Inc., Lena Biosciences is the pioneer of Spot-A-Culture and Spot-A-Drug Platform Technologies and a leading supplier of Spot-A-Culture disposable products for tissue fingerprinting in life sciences and pharmaceutical testing. These versatile tools integrate into existing pharmaceutical workflows and enable customers to model tissues, deliver and test drugs in a convenient all-in-one package. The firm's Spot-A-Culture and Spot-A-Drug tools are compliant with medium- to high-throughput screening assays and high content screening assays for both target-based and phenotypic drug discovery offering the possibility for user customization without capital investments into new equipment and personnel training; thus saving time and money. Lena Biosciences SeedEZ enables scientists to grow cells, test compounds, and assess function with improved physiological relevance. Backed by a National Institutes of Health sSBIR funding and the Georgia Research Alliance Venture Lab grants, this tool has been validated with diverse tissue models serving rapidly expanding 3D cell culture, ADME/Tox screening and high-content screening market with recognized returns in discovery and cost. Lena Biosciences technical core competencies center around patent-protected and patent-pending technologies for engineering tissue equivalents, thick tissue perfusion, incubation, and assay development. Some of these technologies originated in the laboratories of the Georgia Institute of Technology with which the company continues to maintain close ties and a strong collaboration since its spin-off in 2008 as microPerfusions, Inc.develops microperfusion platforms for the diagnosis of thick preparations.
